Mirador
Therapeutics.

A lab in San Diego is betting against guesswork

Inside a building on Headquarters Point, scientists are doing something that sounds almost dull until you realize how rare it is in drug development: they are trying to know, in advance, which patients a medicine will help. Not hope. Know. Mirador Therapeutics treats immune-mediated inflammatory and fibrotic disease, and it treats them the way a cartographer treats unfamiliar territory - with data, before setting out.

The company is young, founded in 2024, but it does not behave like it. It launched with more than $400 million, has since pushed past $650 million in total funding, and runs a multi-asset clinical pipeline aimed at conditions that have frustrated medicine for decades. The unfashionable idea at its center is that biology is knowable if you collect enough of it.

Immunology has an efficacy ceiling

Here is the uncomfortable truth about treating Crohn's disease, ulcerative colitis, rheumatoid arthritis and idiopathic pulmonary fibrosis: even the good drugs only work for some of the people, some of the time. Response rates plateau. A medicine that transforms one patient's life does nothing for the patient in the next room. The industry's polite term for this is "unmet need." The blunt version is that we have been treating these diseases by their symptoms rather than their genetics.

It is a strange thing to celebrate a 40% response rate, and yet for years that was roughly the bar. The reason is structural. Most immune-mediated diseases are not one disease at all - they are several, wearing the same name, driven by different biology in different people. Give them all the same drug and the math is predictable: it helps the ones whose biology matches, and shrugs at the rest.

The team that already did this once

Mark McKenna and his colleagues are not strangers to this problem. Before Mirador, they built Prometheus Biosciences, a precision-immunology company that Merck acquired in 2023 for $10.8 billion. That outcome bought them something more valuable than a track record: a conviction about what works. Prometheus proved that genetics-led patient selection could move the needle. Mirador is the attempt to do it at greater scale, across more diseases, with sharper tools.

The bet is simple to state and hard to execute. Collect enough human genetic and molecular data, harmonize it, and you can find the targets that matter and the patients who will respond - before a single trial begins. Investors found the argument persuasive. ARCH Venture Partners led, with OrbiMed and Fairmount in early, and a syndicate that reads like a who's who of life-sciences capital piled in behind them.

Meet Mirador360

Mirador360 is the engine, and it is the entire thesis in one piece of software-and-science. It harmonizes millions of patient molecular profiles - human genetics, multi-modal data, the noisy fingerprints of real disease - and runs AI and advanced analytics across them. The output is threefold: novel targets worth chasing, combination therapies designed rather than stumbled upon, and the patient populations most likely to actually benefit.

If that sounds like a fancy way of saying "more data," consider what it changes. A traditional pipeline picks a target, makes a drug, and finds out in an expensive Phase 2 whether it works. Mirador's pitch is to front-load that knowledge - to enrich trials for responders from the start. The name is a small joke that happens to be accurate: a mirador is a watchtower, the place you stand to see what is coming.

A short company with a long stride

Money is not data, but it is a vote

Mirador has not yet published the clinical readouts that will make or break it. What it has is conviction expressed in capital - and the kind of investor list that does not assemble by accident. The chart below is not evidence that the science works. It is evidence that a lot of people who are paid to be skeptical decided to find out.

Right drug, right patient, on purpose

Strip away the platform language and Mirador's mission is humane and specific: decode the complicated biology of inflammation and fibrosis into something a doctor can act on. For a person living with Crohn's or pulmonary fibrosis, "precision medicine" is not a slogan - it is the difference between a year of trying drugs that do not fit and a treatment chosen because the biology said it should work.

The company describes itself as science-driven, precision-first and patient-centered, with a noticeable streak of urgency. That urgency is earned. These are chronic diseases that wear people down slowly, and the current toolkit, for all its progress, leaves too many behind.

Back in that San Diego lab

Return to the building on Headquarters Point. The scientists there are still doing the unglamorous work of turning data into decisions. But the stakes are arriving on a schedule now. By the end of 2027, the readouts come - safety and efficacy across multiple programs - and the watchtower will finally have something to look at besides its own forecast.

If the data lands, Mirador will not just have made a few good drugs. It will have offered evidence for a quieter, more durable claim: that the right medicine for the right patient can be known in advance, not discovered by accident. That is the bet. The lab in San Diego is no longer just hoping. It is waiting for the numbers - and, for once, it has a fairly good idea of what they will say.

Find Mirador

Figures and quotes drawn from public company statements and press reporting. Funding totals are approximate; clinical timelines reflect company guidance and may change.